Nuclear Medicine and Molecular Imaging

The Korean Society of Nuclear Medicine (대한핵의학회)
권호 표지

Internal Radiation Dosimetry using Nuclear Medicine Imaging in Radionuclide Therapy

방사성핵종 이용 치료에서 핵의학영상을 이용한 흡수선량평가

  • Kim, Kyeong-Min (Division of Nuclear Medicine and RI Application, Radiological and Medical Sciences Research Center, Korea Institute of Radiological and Medical Sciences) ;
  • Byun, Byun-Hyun (Division of Nuclear Medicine and RI Application, Radiological and Medical Sciences Research Center, Korea Institute of Radiological and Medical Sciences) ;
  • Cheon, Gi-Jeong (Division of Nuclear Medicine and RI Application, Radiological and Medical Sciences Research Center, Korea Institute of Radiological and Medical Sciences) ;
  • Lim, Sang-Moo (Division of Nuclear Medicine and RI Application, Radiological and Medical Sciences Research Center, Korea Institute of Radiological and Medical Sciences)
  • 김경민 (한국원자력의학원 방사선의학연구소 핵의학.RI연구부) ;
  • 변병현 (한국원자력의학원 방사선의학연구소 핵의학.RI연구부) ;
  • 천기정 (한국원자력의학원 방사선의학연구소 핵의학.RI연구부) ;
  • 임상무 (한국원자력의학원 방사선의학연구소 핵의학.RI연구부)
  • Published : 2007.08.31
Download PDF
⟨ Previous Next ⟩

Abstract

Radionuclide therapy has been an important field in nuclear medicine. In radionuclide therapy, relevant evaluation of Internally absorbed dose is essential for the achievement of efficient and sufficient treatment of incurable disease, and can be accomplish by means of accurate measurement of radioactivity in body and its changes with time. Recently, the advances of nuclear medicine imaging and multi modality imaging processing techniques can provide change of more accurate and easier measurement of the measures commented above, in cooperation of conventional imaging based approaches. in this review, basic concept for internal dosimetry using nuclear medicine imaging is summarized with several check points which should be considered In real practice.

Keywords

References

  1. Turner JH, Martindale AA, Boucek J, Claringbold PG, Leahy MF. $^{131}$I-Anti CD20 radioimmunotherapy of relapsed or refractory non‐Hodgkins lymphoma: a phase II clinical trial of a nonmyeloablative dose regimen of chimeric rituximab radiolabeled in a hospital. Cancer Biother Radiopharm. 2003;18:513-24 https://doi.org/10.1089/108497803322287583
  2. Wiseman GA, Kornmehl E, Leigh B, Erwin WD, Podoloff DA, Spies S, et al. Radiation dosimetry results and safety correlations from $^{90}$Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non‐Hodgkin's lymphoma: combined data from 4 clinical trials. J Nucl Med. 2003;44:465-74
  3. Loevinger R, Budinger TF, Watson EE. MIRD primer for absorbed dose calculation. New York: The Society of Nuclear Medicine; 1988
  4. Macey DJ, williams LE, Breitz HB. Liu A, Johnson TK, Zanzonico PB. AAPM report No. 17: a primer for radioimmunotherapy and radionuclide therapy. American Association of Physicists in Medicine; 2001
  5. Macey DJ, williams LE, Breitz HB. Liu A, Johnson TK, Zanzonico PB. AAPM report No. 17: a primer for radioimmunotherapy and radionuclide therapy. American Association of Physicists in Medicine; 2001
  6. 김은실, 김종순, 김은희. 방사선 안전관리. 고창순 편저. 핵의학. 제2판. 서울: 고려의학; 1997. p. 235-51
  7. 임상무, 홍성운. 방사성의약품 치료. 고창순 편저. 핵의학. 제2판. 서울: 고려의학; 1997. p.767-98
  8. Zanzonico PB, Brill AB, Becker DV. Radiation Dosimetry. In: Wagner Jr HN, Szabo Z, Buchanan JW editors. Priciples of Nuclear Medicine. 2nd ed. Philadelphia: W.B.Saunders Company; 1995. p. 106-34
  9. Internal radiation dosimetry. In: Cherry SR, Sorenson JA, Phelps ME. editors. Physics in Nuclear Medicine. 3rd ed. Philadelphia: Saunders; 2003. p.405-25
  10. Sgouros G. Dosimetry of internal emitters. J Nucl Med. 2005;46: 18S-27S
  11. Siegel JA, Thomas SR, Stubbs JB, Stabin MG, Hays MT, Koral KF, et al. MIRD pamphlet no. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med. 1999;40: 37S-61S
  12. Stabin MG, Brill AB. Quantitative Imaging-Based Dosimetry and Treatment Planning in Radionuclide Therapy. In: Zaidi editor. Quantitative Analysis in Nuclear Medicine Imaging. Singapore: Springer; 2006. p.537-62
  13. Kim KM, Lim SM. Inernal Radiation Dosimetry in Radionnuclide Therapy. Nucl Med Mol Imaging. 2006;40:120-6
  14. Bolch WE, Bouchet LG, Robertson JS, Wessels BW, Siegel JA, Howell RW, et al. MIRD pamphlet No. 17: the dosimetry of nonuniform activity distributions‐radionuclide S values at the voxel level. Medical Internal Radiation Dose Committee. J Nucl Med. 1999;40:11S-36S
  15. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the secondgeneration personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023-7
  16. Stabin MG. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 1996;37:538-46
  17. Sgouros G, Barest G, Thekkumthala J, Chui C, Mohan R, Bigler RE, et al. Treatment planning for internal radionuclide therapy: threedimensional dosimetry for nonuniformly distributed radionuclides. J Nucl Med. 1990;31:1884-91
  18. Sgouros G, Chiu S, Pentlow KS, Brewster LJ, Kalaigian H, Baldwin B, et al. Three‐dimensional dosimetry for radioimmunotherapy treatment planning. J Nucl Med. 1993;34:1595-601
  19. Leichner PK, Koral KF, Jaszczak RJ, Green AJ, Chen GT, Roeske JC. An overview of imaging techniques and physical aspects of treatment planning in radioimmunotherapy. Med Phys. 1993;20: 569-77 https://doi.org/10.1118/1.597051
  20. Dewaraja YK, Ljungberg M, Koral KF. Monte Carlo evaluation of object shape effects in iodine-131 SPET tumor activity quantification. Eur J Nucl Med. 2001;28:900-6 https://doi.org/10.1007/s002590100551
  21. Koral KF, Lin S, Fessler JA, Kaminski MS, Wahl RL. Preliminary results from intensity‐based CT‐SPECT fusion in I-131 anti-B1 monoclonal-antibody therapy of lymphoma. Cancer. 1997;80:2538-44 https://doi.org/10.1002/(SICI)1097-0142(19971215)80:12+<2538::AID-CNCR28>3.0.CO;2-C
  22. Koral KF, Zasadny KR, Kessler ML, Luo JQ, Buchbinder SF, Kaminski MS, et al. CT‐SPECT fusion plus conjugate views for determining dosimetry in iodine-131-monoclonal antibody therapy of lymphoma patients. J Nucl Med. 1994;35:1714-20
  23. Ljungberg M, Sjogreen K, Liu X, Frey E, Dewaraja Y, Strand SE. A 3‐dimensional absorbed dose calculation method based on quantitative SPECT for radionuclide therapy: evaluation for $^{131}I$ using monte carlo simulation. J Nucl Med. 2002;43:1101-9
  24. Sgouros G, Squeri S, Ballangrud AM, Kolbert KS, Teitcher JB, Panageas KS, et al. Patient‐specific, 3-dimensional dosimetry in non-Hodgkin's lymphoma patients treated with $^{131}I$-anti-B1 antibody: assessment of tumor dose‐response. J Nucl Med. 2003;44:260-8
  25. Koral KF, Yendiki A, Lin Q, Dewaraja YK, Fessler JA. Determining total I-131 activity within a VoI using SPECT, a UHE collimator, OSEM, and a constant conversion factor. IEEE Trans Nucl Sci 2004;51:611-8 https://doi.org/10.1109/TNS.2004.829605
  26. Sjogreen K, Ljungberg M, Strand SE. An activity quantification method based on registration of CT and whole‐body scintillation camera images, with application to $^{131}I$. J Nucl Med. 2002;43:972-82
  27. Foster D, Barrett P. Developing and testing integrated multicompartment models to describe a single-input multiple‐output study using SAAM II software system. Proc 6th International Radiopharmaceutical Dosimetry Symposium, Oak Ridge, TN: Oak Ridge Associated Universities, 1999:577-99
  28. Carson RE, Huang SC, Phelps ME. BLD - a software system for physiological data handling and model analysis. Proche 5th Annual Symposium on Computer Applications in Medical Care. 1981:562-5
  29. Dewaraja YK, Ljungberg M, Koral KF. Accuracy of $^{131}I$ tumor quantification in radioimmunotherapy using SPECT imaging with an ultra‐high‐energy collimator: Monte Carlo study. J Nucl Med. 2000;41:1760-7
  30. Dewaraja YK, Ljungberg M, Koral KF. Characterization of scatter and penetration using Monte Carlo simulation in $^{131}I$ imaging. J Nucl Med. 2000;41:123-30
  31. Koral KF, Zasadny KR, Ackermann RJ, Ficaro EP. Deadtime correction for two multihead Anger cameras in $^{131}I$ dual-energywindow- acquisition mode. Med Phys. 1998;25:85-91 https://doi.org/10.1118/1.598162
  32. Macey DJ, Grant EJ, Bayouth JE, Giap HB, Danna SJ, Sirisriro R, Podoloff DA. Improved conjugate view quantitation of I-131 by subtraction of scatter and septal penetration events with a triple energy window method. Med Phys. 1995;22:1637-43 https://doi.org/10.1118/1.597423
  33. Koral KF, Dewaraja Y, Li J, Lin Q, Regan DD, Zasadny KR, et al. Update on hybrid conjugate-view SPECT tumor dosimetry and response in $^{131}I$-tositumomab therapy of previously untreated lymphoma patients. J Nucl Med 2003;44:457-64
  34. Loening AM, Gambhir SS, AMIDE: A Free Software Tool for Multimodality Medical Image Analysis, Molecular Imaging, 2003;2: 131-7 https://doi.org/10.1162/153535003322556877